Table 2.

The pattern of TTX in patients receiving combination IFN-α and RBVNo thyroid nuclear or ultrasonic imaging was available for all thyrotoxic cases

Subjects	1	2	3
Gender	F	F	M
Age	26	35	36
HCV Genotype	1a	3a	1g
Regimen duration (weeks)	48	24	24
Adverse reactions	Myalgia, lethargy, emotional lability	None	Insomnia, rash
Baseline ALT	184	142	104
ALT at time of thyroid disease	33	28	17
Duration of therapy prior to thyroid disease (weeks)	16	8	32
Symptoms of thyroid disease	Anxiety and depression	Non-specific	Non-specific
Signs	No goitre	No goitre	No goitre
Peak fT4 (pmol/L)	56.7	57.0	27.0
Peak fT3 (pmol/L)	15.1	15.3	12.8
Thyroid autoantibody status	• Anti-Tg <1 • Anti-TPO 1:409,600 • TSI <1	• Anti-Tg <1 • Anti-TPO 1:409,600 • TSI <1	• Anti-Tg <1 • Anti-TPO <1:100 • TSI <1
Thyroid outcomes	Hypothyroidism on replacement therapy	Hypothyroidism on replacement therapy	Thyroid condition resolved with IFN-α dose reduction
Hepatic outcomes	PCR negative	PCR negative	PCR negative